Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…<p>(A) Ki-67 expression in parathyroid glands of rats with CKD-induced sHPT treated with Cinacalcet either early in the inactive light phase (<i>Cina1</i>; N = 10) or early in the active dark phase (<i>Cina2</i>; N = 9) compared to untreated rats with sHPT investigated at similar time points (<i>PNX1</i>; N = 7 and <i>PNX2</i>; N = 7, respective) and to normal rats investigated at similar time points (<i>ctrl1</i>; N = 9 and <i>ctrl2</i>; N = 7, respective). …”

Conditional ablation of <i>Ybx1</i> leads to a reduction in cortical progenitor cell pool and a decrease in cortical thickness. by Jian Zhang (1682)

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

Subjects:

DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

“…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”

Overview of the WeARTolerance program. by Ana Beato (20489933)

“…The quantitative results from Phase 1 demonstrated a decreasing trend in all primary outcomes. …”

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Subjects:

General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

HSF2 regulates lytic gene expression in latency and during the lytic phase. by Lorenza Cutrone (21144285)

Subjects:

The parameters of gas exchange markedly decreased in maize <i>zmstomagen1/2</i> mutant compared with in wild type (WT). by Juan-Juan Xu (18590868)

Primers used in ChIP-PCR. by Lorenza Cutrone (21144285)

Subjects:

Primers used in RTqPCR. by Lorenza Cutrone (21144285)

Subjects:

(A) The circadian clock model and (B) the relevance of waveform characteristics to temperature compensation (<i>magenta</i>) and synchronization (<i>cyan</i>). by Shingo Gibo (21762920)

(A–D) Representative immunoblots for the reporter assays shown in Fig 4A–D. by Lorenza Cutrone (21144285)

Subjects:

A. Quality of evidence: TOTVA vs. COT. B. Quality of evidence: TOTVA vs. NTET (including robotic approaches). by Huixia Ren (500186)

Subjects:

(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. by Lorenza Cutrone (21144285)

Subjects:

HSF2 is a positive regulator of EBV spontaneous lytic cycle in gastric epithelial cells. by Lorenza Cutrone (21144285)

Subjects: